Albumin excretion during puberty in the setting of type 1 diabetes.

The use of an ACE inhibitor and a statin did not change the albumin-to-creatinine ratio over time among adolescents with type 1 diabetes. Neither drug had significant effects on carotid intima–media thickness, other cardiovascular markers, the glomerular filtration rate, or progression of retinopathy.

NEJM

 

Also see:

Victoza and kidney prevention in type 2 diabetes

Jardiance improves urinary protein leak

Invokana, Diabetes, Heart, Kidney and Amputations.

 

 

 


N  E  J  M

Randomized 

November 2017

 

BACKGROUND:

Among adolescents with type 1 diabetes, rapid increases in albumin excretion during puberty precede the development of microalbuminuria and macroalbuminuria, long-term risk factors for renal and cardiovascular disease. We hypothesized that adolescents with high levels of albumin excretion might benefit from angiotensin-converting–enzyme (ACE) inhibitors and statins, drugs that have not been fully evaluated in adolescents.

 

METHODS:

We screened 4407 adolescents with type 1 diabetes between the ages of 10-16 years of age and identified 1287 with values in the upper third of the albumin-to-creatinine ratios; 443 were randomly assigned in a placebo-controlled trial of an ACE inhibitor and a statin with the use of a 2-by-2 factorial design minimizing differences in baseline characteristics such as age, sex, and duration of diabetes.

The primary outcome for both interventions was the change in albumin excretion, assessed according to the albumin-to-creatinine ratio calculated from three early-morning urine samples obtained every 6 months over 2-4 years, and expressed as the area under the curve.

Key secondary outcomes included the development of microalbuminuria, progression of retinopathy, changes in the glomerular filtration rate, lipid levels, and measures of cardiovascular risk (carotid intima–media thickness and levels of high-sensitivity C-reactive protein and asymmetric dimethylarginine).

 

RESULTS:

The primary outcome was not affected by ACE inhibitor therapy, statin therapy, or the combination of the two. The use of an ACE inhibitor was associated with a lower incidence of microalbuminuria than the use of placebo; in the context of negative findings for the primary outcome and statistical analysis plan, this lower incidence was not considered significant.

Statin use resulted in significant reductions in total, LDL, and non–HDL levels, in triglyceride levels, and in the ratio of apolipoprotein B to apolipoprotein A1, whereas neither drug had significant effects on carotid intima–media thickness, other cardiovascular markers, the glomerular filtration rate, or progression of retinopathy.

Overall adherence to the drug regimen was 75%, and serious adverse events were similar across the groups.

 

CONCLUSIONS:

The use of an ACE inhibitor and a statin did not change the albumin-to-creatinine ratio over time.